Press Release: Omeros : Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros'
Read full article »
Omeros is a Wasington-based biopharmaceutical company that researches and develops small-molecule and protein therapeutics for the treatment of inflammation and CNS disorders.
Read more